ziprasidone (geodon) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ziprasidone is atypical antipsychotic, approved by the U.S. Food and Drug Administration for the treatment of schizophrenia, and acute mania and mixed states associated with bipolar disorder. Intramuscilar injections of Ziprasidone are indicated for rapid control of the agitation in schizophrenic patients. Ziprasidone is used off-label for treatment of major depressive disorder, anxiety, obsessive compulsive disorder, borderline personality disorder. Ziprasidone functions as an antagonist at the D2, 5HT2A, and 5HT1D receptors, and as an agonist at the 5HT1A receptor.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.3011 - $49.4050

Australia

$0.5763 - $2.3038
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one | cp 88059 | cp-88059 | cp-88,059 | cp 88059-01 | cp-88,059-01 | cp-880591 | cp-88,059-1 | cp-88059-1 | cp-8805927 | cp-88059-27 | geodon | zaprasidone | zeldox | ziprasidona | ziprasidone | ziprasidone hcl | ziprasidone hydrochloride | ziprasidone hydrochloride, monohydrate | ziprasidone mesilate | ziprasidone mesylate | ziprasidonum | ziprazidone

Organizations (110)

Research & Development (94)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (2)


 

Bipolar Disorder

Schizophrenia (approved 2001)

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Affective Disorders, Psychotic (Phase 4)

Analgesics, Opioid (Early Phase 1)

Antipsychotic Agents (Phase 4)

Anxiety (Phase 4)

Anxiety Disorders (Phase 4)

Attention Deficit and Disruptive Behavior Disorders (Phase 2)

Autistic Disorder (Phase 2)

Behavior, Addictive (Early Phase 1)

Bipolar Disorder (Phase 4)

Borderline Personality Disorder (Phase 2)

Cardiovascular Diseases (Phase 1)

Cognition Disorders (Phase 3)

Conduct Disorder (Phase 2)

Delirium (Phase 4)

Dementia (Phase 3)

Depression (Phase 4)

Depressive Disorder, Major (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 4)

Hyperglycemia (Phase 4)

Insulin Resistance (Phase 4)

Mania (Phase 4)

Medication Adherence (Phase 4)

Mental Health (Phase 4)

Metabolic Syndrome (Phase 4)

Mood Disorders (Phase 4)

Opioid-Related Disorders (Early Phase 1)

Panic Disorder (Phase 4)

Phobia, Social (Phase 2)

Psychology, Clinical (Phase 3)

Psychophysiologic Disorders (Phase 3)

Psychotic Disorders ()

Risk Factors (Phase 4)

Schizophrenia (Phase 4)

Schizophrenia, Paranoid (Phase 4)

Schizophrenia Spectrum and Other Psychotic Disorders (Phase 4)

Stress Disorders, Post-Traumatic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 120
  • # of Trial Organizations: 94

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue